Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Active not recruiting 2Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2

Conditions

Prostatic Neoplasms 42Lung Neoplasms 39Leukemia, Myeloid, Acute 38Carcinoma, Non-Small-Cell Lung 33Neoplasm Metastasis 29Breast Neoplasms 27Myelodysplastic Syndromes 21Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 18Pancreatic Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Triple Negative Breast Neoplasms 15Multiple Myeloma 15Ovarian Neoplasms 14Glioblastoma 14Squamous Cell Carcinoma of Head and Neck 13Carcinoma, Renal Cell 13Burkitt Lymphoma 13Urinary Bladder Neoplasms 10Mouth Neoplasms 10Melanoma 10Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma 10Oropharyngeal Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Laryngeal Neoplasms 9Brain Neoplasms 9

Interventions

Specimen Handling 3Azacitidine 3ruxolitinib 2Melphalan 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1posaconazole 1onvansertib 1merphos 1gilteritinib 1fludarabine phosphate 1fludarabine 1fedratinib 1axatilimab 1Whole-Body Irradiation 1Watchful Waiting 1Tranexamic Acid 1Tacrolimus 1Succimer 1Stem Cell Transplantation 1Rituximab 1Positron-Emission Tomography 1Pentetic Acid 1Methotrexate 1Janus Kinase Inhibitors 1Injections 1Hyperbaric Oxygenation 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic-Myeloproliferative Diseases × Specimen Handling × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT05549661 2026-02-23

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Mayo Clinic

Phase 1 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡